Dinaciclib
Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs). It is being evaluated in clinical trials for various cancer indications. Dinaciclib is being developed by Merck & Co. It was granted orphan drug status by the FDA in 2011.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370865399 under CC BY-SA 4.0; modifications have been made.